Aspen Neuroscience’s Sasineprocel Receives RMAT Designation in Parkinson’s Disease

Company: Aspen Neuroscience · Event Type: Regulatory Designation · Modality: Autologous iPSC-Derived Cell Therapy · Product: Sasineprocel (ANPD001) · Target Indication: Parkinson’s Disease · Designation Date: July 30, 2026 Summary The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Aspen Neuroscience’s sasineprocel (ANPD001),…